Skip to main content

Day: September 21, 2020

Savaria annonce la nomination d’un nouveau chef de la direction financière

LAVAL, Québec, 21 sept. 2020 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, a le plaisir d’annoncer la nomination de M. Stephen Reitknecht au poste de chef de la direction financière de Savaria, effectif le 21 septembre 2020.Mot du président« M. Reitknecht est titulaire d’un C.P.A. et possède 15 ans d’expérience dans divers secteurs, notamment les équipements médicaux et la distribution en gros. Il apporte de solides connaissances en consolidation multidevises, intégration d’équipes de soutien, normes IFRS et US GAAP et intégration d’acquisitions. M. Reitknecht travaillera principalement à partir de l’usine de fabrication de Brampton, en Ontario, Canada, où le vice-président des opérations et le chef de la direction de la société sont...

Continue reading

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by IncyteROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $15 million milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012), an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA00012). The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous...

Continue reading

BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Topline proof-of-concept results in ADH1 anticipated in 2021Currently, there are no approved therapies for ADH1PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center study of encaleret (CLTX-305) in individuals with ADH1 conducted at the National Institutes of Health. ADH1 is a rare, inherited disease caused by gain-of-function mutations in the calcium sensing receptor (CaSR) resulting in abnormally low serum calcium and high urine calcium and a range of debilitating symptoms. Encaleret sulfate is an investigational oral therapy being studied to address ADH1 at its source by antagonizing the CaSR.“Patients with ADH1 are currently treated with calcium supplements with a goal of raising their serum calcium...

Continue reading

Russ Girling to retire as President and CEO

CALGARY, Alberta, Sept. 21, 2020 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE:TRP) (TC Energy or the Company) today announced Russ Girling’s retirement as President and Chief Executive Officer and from its Board of Directors effective December 31, 2020. François Poirier, currently Chief Operating Officer, President, Power & Storage and Mexico, will succeed Mr. Girling as President and Chief Executive Officer and will join the Board January 1, 2021. Mr. Girling will assist Mr. Poirier with the transition through February 28.“On behalf of all Board members, I would like to thank Russ for his invaluable contributions to the Company,” says Siim Vanaselja, Chairman of the Board of Directors. “Over the last decade, he has led TC Energy through a period of unprecedented growth and transformation, including the development of...

Continue reading

Purge Virus Launches Clean Room Initiative to Help Homeowners at Risk from Western U.S. Wildfires

Chicago, IL, Sept. 21, 2020 (GLOBE NEWSWIRE) — FOMO CORP. (US OTC: ETFM)–Under an LOI to merge with FOMO this Fall, Purge Virus LLC (PV) is pleased to announce its Clean Room Initiative (CRI) to help home and business owners at risk from Western U.S. wildfires. For more on the portable devices see: https://purgevirus.com/portable-devices/According to the Lawrence Berkley National Laboratory, “People in the U.S. and many other developed countries are indoors approximately 90% of the time, and may be indoors even more when outdoor air is affected by wildfires When outdoor air particle concentrations increase, indoor air concentrations of particles also increase, particularly in homes because they usually have low efficiency particle filtration systems or no particle filtration.”The recent wildfires have caught the attention of the world,...

Continue reading

Theratechnologies Announces Preliminary Third-Quarter Fiscal 2020 Financial Results

MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020.For the third quarter of fiscal year 2020, the company expects consolidated net revenues to be between $13.8 million and $14.2 million compared to $16.1 million for the third quarter of fiscal year 2019. Revenues for the third quarter of 2020 were primarily impacted by the COVID-19 pandemic, one-time items related to the transition from EGRIFTA® to EGRIFTA SV® as well as higher than expected rebates and chargebacks related to prior reporting periods.“In addition to one-time items impacting our third quarter revenues, COVID-19...

Continue reading

Purge Virus Launches Clean Room Initiative to Help Homeowners at Risk from Western U.S. Wildfires

Chicago, IL, Sept. 21, 2020 (GLOBE NEWSWIRE) — FOMO CORP. (US OTC: ETFM)–Under an LOI to merge with FOMO this Fall, Purge Virus LLC (PV) is pleased to announce its Clean Room Initiative (CRI) to help home and business owners at risk from Western U.S. wildfires. For more on the portable devices see: https://purgevirus.com/portable-devices/According to the Lawrence Berkley National Laboratory, “People in the U.S. and many other developed countries are indoors approximately 90% of the time, and may be indoors even more when outdoor air is affected by wildfires When outdoor air particle concentrations increase, indoor air concentrations of particles also increase, particularly in homes because they usually have low efficiency particle filtration systems or no particle filtration.”The recent wildfires have caught the attention of the world,...

Continue reading

Dentures Market to Increase at a CAGR of 6.4% and Reach USD 3.82 Billion by 2027 Owing to Rising Number of Periodontal Diseases: Fortune Business Insights™

Pune, Sept. 21, 2020 (GLOBE NEWSWIRE) — The global dentures market size is expected to rise remarkably on account of the increasing prevalence of dental issues and periodontal diseases worldwide. Dentures are customized artificial teeth gums that are replaced with lost or removed teeth. They are shaped accordingly as per the oral structure of the patient. As per a recently published report by Fortune Business Insights™ titled, “Dentures Market Size, Share & Industry Analysis, By Type (Complete and Partial), By Usage (Removable and Fixed), By End User (Dental Hospitals & Clinics, Dental Laboratories, and Others), and Regional Forecast, 2020-2027,” the market stood at USD 2.33 billion in 2019 and is anticipated to reach USD 3.82 billion by 2027 by exhibiting a CAGR of 6.4% between 2020 and 2027.Highlights of the Report:Analysis...

Continue reading

Contraceptives Market to Exhibit 5.5% CAGR and Reach USD 30.15 Billion by 2027; Increasing Rates of Unwanted Pregnancies in North America to Favor Growth: Fortune Business Insights™

Pune, Sept. 21, 2020 (GLOBE NEWSWIRE) — The global contraceptives market is set to gain traction from the increasing adoption of low-dose combined oral contraceptives (COCs). They include progestogen blended with 20-35 micrograms of ethinylestradiol. This information is given by Fortune Business Insights™ in a new report, titled, “Contraceptives Market Size, Share & COVID-19 Impact Analysis, By Product (Contraceptive Drugs and Contraceptive Devices), By Gender (Male & Female) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Channel, Clinics, Public Channel & NGOs, and Others), and Regional Forecast, 2020-2027.” The report further states that the market size was USD 22.49 billion in 2019 and is projected to reach USD 30.15 billion by 2027, exhibiting a CAGR of 5.5% during the forecast period.This...

Continue reading

Cend Therapeutics Announces Acquisition of Impilo Therapeutics

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of nucleic acid-based medicines to solid tumor cancers.While antisense and siRNA medicines have reached market for a range of metabolic, neurological and neuro-muscular conditions, none have reached market for anticancer applications. “By combining Impilo with Cend our objective is to address delivery issues that have limited the ability of nucleic acid-based medicines to benefit cancer patients,” commented David Slack, CEO of Cend.“Cend’s lead asset, CEND-1, has generated encouraging clinical data showing the ability to enhance delivery of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.